Efficacy and safety of rabeprazole in non-steroidal anti-inflammatory drug-induced ulcer in Japan

Figure 1 Patient disposition. ¹Patients treated for longer than the allowed treatment period. The allowed treatment period was defined in the protocol as 8 wk for patients with gastric ulcer and 6 wk for patients with duodenal ulcer, + 2 wk for each (i.e. 10 wk for gastric ulcer and 8 wk for duodenal ulcer); ²Patients for whom endoscopic evaluation was performed prior to 31 d before the start of rabeprazole treatment or more than 31 d after the conclusion of rabeprazole treatment.